Safety and Efficacy of Paxlovid in Pediatric Intensive Care Unit Patients with COVID-19

Panpan Fan; Meixiu Ming; Tingyan Liu; Weiming Chen; Yixue Wang; Dan Wang; Guoping Lü; Gangfeng Yan

doi:10.2174/0109298673313885240621110518

July 2, 2024Current Medicinal Chemistry

Safety and Efficacy of Paxlovid in Pediatric Intensive Care Unit Patients with COVID-19

View at Publisher

Ask AI

Bookmark

Share

Key Points

Clinical efficacy and safety of paxlovid remain uncertain in pediatric intensive care unit populations, whereas adult use has received endorsement across several clinical guidelines.
Assessment of nirmatrelvir and ritonavir focuses on critically ill young patients, but available clinical data remain strictly limited to adult therapeutic treatment recommendations.
Highlights the urgent need for dedicated pediatric intensive care trials, as therapeutic protocols for covid 19 cannot be safely extrapolated from adult evidence without verification.

Abstract

Paxlovid (nirmatrelvir/ritonavir) has received endorsement from several guidelines for treating COVID-19 in adults, but its use in children is still uncertain.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fan et al. (2024) studied this question.

synapsesocial.com/papers/68e61b61b6db6435875ad4f8 https://doi.org/10.2174/0109298673313885240621110518

View at Publisher

Ask AI

Bookmark

Share

Safety and Efficacy of Paxlovid in Pediatric Intensive Care Unit Patients with COVID-19

Key Points

Abstract

Discussion

Cite This Study

Safety and Efficacy of Paxlovid in Pediatric Intensive Care Unit Patients with COVID-19

Key Points

Abstract

Discussion

Cite This Study

Keep reading

Keep reading